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The skin-associated lymphoid tissue is composed of 
keratinocytes, Langerhans cells, skin trophic T cells, 
and lymphatic endothelial cells of the skin. The 
epidermis, which is involved in many viral infections, 
contains all of the components needed for an effec­
tive immune response: antigen-presenting Langer­
hans cells, T cells, and cytokines from leukocytes and 
keratinocytes. There have been some recent advances 
in the study of the cutaneous immunology involved 
in infections with the human immunodeficiency virus 
(HIV), human papillomavirus (HPV). and herpes sim­
plex virus (HSV). In general, viral diseases with cuta­
neous manifestations lead to a decline in epidermal 
Langerhans cell numbers, which probably reflects 
Langerhans cell emigration out of the epidermis and 
entry into regional lymph nodes, leading to Langer­
hans cell activation and antigen presentation to T 
T he skin is a site that allows primary immune sensiti­zation, retains immunologic memory, houses immu­nocytes, and is preferentially affected by T-cell ma­lignancies. In 1978, Streilein [1] proposed, based upon the above information, that there is a specific 
relation between the immune system and the integument, much 
like the gut-associated lymphoid tissue, and proposed the concept 
of skin-associated lymphoid tissue (SALT) [2]. SALT is made up of 
the following: 1) keratinocytes, which can phagocytize, release 
many cytokines, and even express major histocompatibility com­
plex (MHC) class II antigens upon incubation with interferon 
(lFN)-y; 2) epidermal Langerhans cells, which have surface expres­
sion of MHC class II, CD1, C3biR, and CD4 molecules, and are 
the predominant scavenger antigen-presenting cell of the epider­
mis; 3) skin trophic T cells, which in the epidermis include mainly 
"inactive" memory T cells of predominantly CD8+ phenotype, 
although CD4+ and CD4- CD8- y8+ T cells are also present; 
and 4) skin endothelial cells, which direct cellular traffic in and out 
of the skin. The epidermis contains the basic elements needed for an 
immune response (T cells, antigen-presenting cells, and cytokines), 
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cells. In HSV, there is a subsequent T-cell infiltration 
of the epidermis, composed of CD4+ cells that have 
both immune modulatory action and direct cytotoxic 
action. In mv, where there is a systemic depletion of 
CD4+ cells, the epidermis is left with reduced num­
bers ofT cells. Intradermal injection of interleukin-2, 
however, leads to an epidermal cellular infiltration in 
HIV + individuals. In HPV -induced condyloma, in­
tralesional interferon increases Langerhans cells and 
CD4+ and CD8+ cells in the skin, as well as trans­
forming growth factorpl, tumor necrosis factor-a, 
pRB, and pS3. Therefore, viral infections involving 
the epidermal immune system have certain similar 
characteristics, whereas other factors are unique to 
the infecting virus. Key words: SALT!viral infection! 
epidermis. J Invest Dermatol 105:99S-104S, 1995 
and because of its anatomic structure, serves as a primary line of 
defense against infections. Therefore, we review three viruses with 
cutaneous manifestations and their interactions with the compo­
nents of SALT. 
HUMAN IMMUNODEFICIENCY VIRUS (HIV) 
HIV is the causative agent of the acquired immune deficiency 
syndrome (AIDS). HIV is a retrovirus, which can incorporate into 
cellular DNA using reverse transcriptase. HIV infection leads to a 
progressive weakening of cell-mediated immune function and a 
progressive decline in the numbers of peripheral blood CD4+ cells. 
The effect on the humoral immune system is hypergammaglobu­
linemia, which allows diagnosis but is not sufficient to eliminate 
HIV infection. HIV has a particular tropism for activated CD4+ 
cells [3], but professional phagocytes carrying the proviral form of 
HIV have been isolated from patients [4]. Because the skin contains 
CD4+ cells and antigen-presenting cells, it would not be surprising 
to find HIV in the epidermis. 
Skin biopsy specimens from seven of 40 HIV + individuals 
reacted with anti-HIV-1 core protein p17 in an indirect immuno­
fluorescence assay [5]. The only cells that could be detected to be 
infected with HIV were Langerhans cells, although Heng et al [6] 
have shown that keratinocytes, which do not express CD4, can be 
coinfected with herpes simplex virus-1 (HSV-1) and HIV in vivo. 
Berger et al [7] demonstrated that Langerhans cells could be 
infected with HIV in vitro and that Langerhans cells from HIV + 
individuals could infect mononuclear phagocytes from HIV -
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individuals. Cimarelli et al [8] quantified the promal DNA in 
Langerhans cells and found that the frequency of HIV -infected 
Langerhans cells is comparable to the frequency of peripheral blood 
CD4+ T cells infected with HIV in AIDS patients. Two important 
questions arise: How are the Langerhans cells infected? and How do 
they contribute to the pathology associated with AIDS? 
Langerhans cells normally reside in the epidermis, and upon 
activation migrate to the draining lymph nodes, where there is 
contact with T cells. It is not known where Langerhans cells 
become infected with HIV. Langerhans cells could be infected with 
HIV in the epidermis by direct inoculation. This is particularly 
plausible in coinfection scenarios, in which, for example, a herpetic 
lesion has compromised the cornified layer of the epidermis, 
attracting and activating CD4+ cells and rendering Langerhans 
cells and other cells vulnerable to HIV infection. These infected 
Langerhans cells could leave the epidermis to reside in the regional 
lymph nodes, in the process infecting activated CD4+ cells. 
Because certain subpopulations ofT cells preferentially home to the 
integument, the likelihood that an infected T cell would infect a 
Langerhans cell is greater. This is particularly plausible in light of 
the finding by Pantaleo et al [9] that the HIV viral load in lymph 
nodes is significandy higher than that in peripheral blood. 
Although there is some controversy, many groups have shown a 
significant reduction of epidermal Langerhans cells in HIV + indi­
viduals [10]. Whether the paucity of epidermal Langerhans cells is 
due to emigration out of the epidermis or cell death is not known. 
Certainly, activated Langerhans cells do leave the epidermis, but if 
this were the case, why don't they eventually repopulate the 
epidermis? HIV infection has definite cytopathic effects on Langer­
hans cells. Cell death in conjunction with migration out of the 
epidermis could explain the paucity of Langerhans cells in the 
epidermis. 
Cytokines also influence HIV -infected Langerhans cells. Leonard 
et al [11] created a transgenic mouse with the HIV long terminal 
repeat, which contains all known HIV transcriptional response 
elements, linked to a reporter gene. Langerhans cells from the 
mouse skin had higher reporter gene activity than other cells of the 
monocyte/macrophage lineage, indicating that HIV provirus is 
especially inducible in Langerhans cells. The transgenic mouse 
macrophages incubated in the presence of colony-stimulating fac­
tor-I, granulocyte macrophage- colony-stimulating factor, inter­
leukin (IL)-la, IL4, and IL2 had much higher reporter gene activity 
than macrophages incubated in the absence of these cytokines. This 
indicates that the above cytokines up-regulate HIV transcription 
and possibly facilitate cytopathy. Because these cytokines are 
involved in SALT, it would be significant to elucidate their role in 
human skin from HIV+ patients. Dreno et al [12] showed a 
correlation between levels of IL-l in normal skin ofHIV+ patients 
and the stage of disease, which has been shown previously to 
correlate with epidermal Langerhans cell numbers. Using the 
Centers for Disease Control classification, all stage II HIV + 
patients had high levels of intraepidermal IL-1. Normally, IL-l is 
made constitutively by keratinocytes, whereas Langerhans cells 
make IL-l upon activation and depend upon it for proper matura­
tion [13]. IL-l is essential for an antigen-specific immune response, 
leading to IL-2 release from T cells and initiation of an immune 
response. Dreno et al [12] detected fewer stage III HIV + patients 
with intraepidermal IL-l, and even less IL-l in stage IVc and IVd 
patients. Because activated Langerhans cells make IL-1 and it has 
been established that epidermal Langerhans cell numbers decrease 
as HIV infection progresses, it is plausible to assume that the paucity 
of Langerhans cells leads to the decrease in IL-1. The low IL-l 
levels would lead to low levels of other cytokines in the epidermis, 
especially IL-2, rendering the epidermis sterile of immunocytes, 
vulnerable to infection and neoplasm, and nonresponsive (anergic) 
to recall antigens. 
McElrath et al [14] injected recombinant IL-2 intradermally into 
HIV + patients. Symptom-free HIV + individuals reportedly have 
reduced intraepidermal CD4+ cell counts [15], but after IL-2 
injection, there was a local accumulation ofT cells, monocytes, and 
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Langerhans cells. Although peripheral blood CD4+ epidermal 
infiltration is normally reduced in HIV + patients, IL-2 induced a 
CD4 + infiltrative response equivalent to that in HIV - individuals. 
The IL-2 injection also enhanced the response to recall antigen. 
Therefore, IL-2, which is usually made by T cells in response to 
IL-1 and is more specifically made by Thl or ThO cells, converted 
a relatively sterile epidermis into an antigen-responsive milieu. 
The great majority of T cells in the human epidermis have a{3 
T-cell receptors and some y/) receptors, which lack the coreceptors 
CD4 and CD8 [16] and whose function in the epidermis is 
unknown. In mice, the majority of epidermal T cells are dendritic 
y/) cells. In humans, epidermal y/) cells are not dendritic and are 
involved in many diseases. CDl, which is expressed on Langerhans 
cells, can act as an antigen-presenting molecule for y/) T cells [17]. 
The y/) cells, through non-MHC-restricted cytolytic activity, con­
tribute greatly to immune surveillance against malignancies and 
viral infections [18]. Because of the numerous infectious, neoplas­
tic, and idiopathic cutaneous manifestations of HIV, it is possible 
that y/) cells are either involved or affected in the skin of HIV + 
patients. Given the effects of HIV on y/) cells in other lymphoid 
tissues, we will speculate as to potential effects ofHIV on the 1'/) T 
cells of the epidermis. In HIV infection, local 1'/) subtype ratios of 
bronchial-associated lymphoid tissue are altered relative to levels in 
HIV - individuals [19], indicating that HIV infection affects the 
tissue-resident 1'/) T cells and could potentially affect the y/) T cells 
of SALT. Hermier et al [20] observed higher 1'/)+ cells in the blood 
of group II/III patients than in that of group IV c1 and IV d patients. 
HIV + patients with oral candidiasis had even lower blood 1'/) T-cell 
counts. Unfortunately, it is not known whether y/) counts increase 
or decrease in the epidermis ofHIV+ individuals. Indirect immu­
nofluorescence assays of punch biopsy specimens of skin using 
pan-y/) antibodies should be a simple and important method of 
answering this question. 
HIV infection also affects the endothelial component of SALT. 
HIV -infected cells release many different cytokines, tumor necrosis 
factor (TNF)-a being the most common [21]. TNF-a promotes 
endothelial leakiness by inducing cytokine release, IL-1 in partic­
ular; expression of adhesion molecules; and direct enhancement of 
endothelial permeability. Fnrthermore, the HIV-derived transacti­
vator tat protein, which is secreted into extravascular tissue, 
direcdy stimulates endothelial cells to express E-selectin, which is 
necessary for endothelial trapping of leukocytes in the vasculature. 
In addition, tat enhances IL-6 synthesis, which increases endothelial 
permeability, facilitating leukocyte passage out of the vasculature 
[22]. The above scenario can potentially aid in the dissemination of 
HIV -infected cells into virus-free tissue. 
In summary, it is conceivable that HIV -sensitive Langerhans cells 
are infected with HIV in the lymph nodes, and in the cytokine-rich 
milieu of the epidermis, enhanced HIV cytopathy leads to Langer­
hans cell death and reduced epidermal Langerhans cell numbers. 
This renders the epidermis relatively sterile of functioning immune 
cells and vulnerable to infections, malignancies, and immune 
dysregulations, which would explain a lack of response to recall 
antigens in late HIV infection. If exogenous cytokines such as IL-2 
are supplemented, there is once again temporary repopulation of 
the skin and immune responsiveness. 
HUMAN PAPILLOMAVIRUS (HPV) 
HPV is a DNA virus that gains entry into the epidermis through a 
structural break in the skin, remains in the basal layer, and replicates 
just below the granular layer. giving rise to a slowly growing lesion. 
There are more than 70 different recognized HPV genotypes. HPVs 
are categorized based on regional tropism and potential for malig­
nant transformation. For example, HPVs 6 and 11 are trophic for 
the genital skin and mucous membranes and produce condyloma 
acuminata, which presents a low risk for malignant transformation. 
Epidermodysplasia verruciformis (EV) is an HPV-associated disease 
presenting with persistent, disseminated wart-like lesions on the 
skin. and is commonly associated with HPVs 5 and 8. One third of 
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patients with EV eventually experience malignant transfonnation of 
the HPV -infected lesions. 
The successful clearance ofHPV from the epidennis is dependent 
upon an intact immune system. Among immunosuppressed trans­
plant
. 
patients, 77% even�ally develop viral warts [23]. Recently, 
certam aspects of the active role of SALT in HPV infections have 
been elucidated. Cutaneous viral infections in general lead to a 
reduction in the numbers of epidennal Langerhans cells [24]. 
Generally, fiat wart lesions are accompanied by CD4+ and CD8+ 
cellular infiltrates, a reduction in epidennal Langerhans cells an 
increase in dennal Langerhans cells, and the appearance of hu:nan 
leukocyte antigen (HLA)-DR + cells in the dennis. Furthennore, 
lesions' with HPV viral antigen are more likely to have reduced 
Lang�rhans cells and HLA-DR + cell counts in the epidennis [25]. 
Kerannocytes are known to express HLA-DR in HPV infections, 
but not HLA-I?Q, so the HLA-DR in the lesion most likely 
represents keratmocytes and not Langerhans cells. Viac et al [26] 
observed HLA-DR + keratinocytes only in condyloma and laryn­
geal papillomas, and not in plantar and hand warts. The expression 
of HLA-DR directly correlated with the intraepithelial up-regula­
tion of intercellular adhesion molecule (ICAM)-1 and lymphocyte 
function-associated antigen-1. ICAM-1 is expressed on keratino­
cytes in condyloma, and not in fiat warts. Lymphocyte function­
associated antigen-1, the natural ligand ofICAM-1, is expressed on 
lymphocytes and is a means of directing lymphocyte traffic to the 
epidennis in this case. Nonnal epidennis does not express ICAM-1, 
but dennal endothelial cells do express low levels ofICAM-1 under 
Donnal conditions. The up-regnlation of ICAM-1 and other adhe­
sion molecules, leading to lymphocytic infiltration, along with 
up-regulation ofHLA-DR in the epidennis, could facilitate antigen 
presentation to infiltrating CD4+ T cells, leading to clearance of 
infection. 
. 
W � �ave addressed the role of HPV pathology in the skin by 
Identifying HPV gene products and the immunologic and cellular 
responses in patients. We probed for TNF-a and transforming 
growth factor (TGF)-f31Ievels in HPV 6- and ll-induced condy­
lomas �nd found a dramatic reduction in their levels compared with 
those m nonnal skin [27]. Majewski et al [28] found increased 
expression of TNF-a and TGF-f31 in EV lesions. The disparity of 
:r�F-a and TGF-f31 levels between EV and condyloma might 
�dica�e part of the underlying defect in EV patients, possibly 
mvolvmg lack of a proper T-cell repertoire [29] to mount a 
regulatory or effector function, a cytokine receptor defect [30], or 
active neutralization of the cytokines by HPV products [31] . 
The viral oncoproteinl cellular protein interactions are well 
established in "high-risk" HPV types, but very little is known 
concerning lesions caused by "low-risk" HPV types. mRNAs of 
the early E2, E5, E6, and E7 HPV genes, as well as the late L1late 
genes, can be detected by reverse transcriptase-polymerase chain 
reaction [27] in low-risk HPV-containing condylomas (Fig t). 
Especially important is the abundance of E7 and E2 messages, 
because t�e f�nner can interact with cellular factors inducing 
hyperproliferatlon and the latter regulates expression of HPV 
gen�s: The L.1 ge.ne enc�des the major capsid protein and can play a cnncal anngeruc role m cellular immunity. Viral oncoproteins, 
such �s high-risk E6 and E7, can interact with cellular regulatory 
protems (e.g., p53, pRB, E2F), displacing them in certain cellular 
p�th�ays. Low-risk E6 and E7 proteins probably are not capable of 
bmding those 
.
cellular proteins, or at least bind with lower affinity, 
y�t they are snll able to transregulate certain host genes, as do their 
htgh-risk counterparts [32,33]. 
. �. condyloma lesions, we found decreased levels of growth­
mhibltory genes (TGF-f31 , IFN-f3, and p53). We detected in­
creased mRNA levels ofhyperphosphorylated (inactive) retinoblas­
toma tumor suppressor gene product (pRB), reduced levels of p53 
tumor suppressor gene product, increased levels of cdc-kinase and 
increased levels of c-myc. Although HPV s 6 and 11 are low risk for 
malignant progression, the condyloma lesional milieu is conducive 
to proliferation, i.e., a slow-growing lesion. Elevated cdc kinase 
levels lead to elevated cdc protein levels, presumably allowing 
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Figure 1. Viral gene expression in condylomas. Viral gene mRNA 
levels were detennined by reverse transcriptase-polymerase chain reaction 
using RNAs isolated from Merent condyloma specintens. The mRNA 
levels of those genes were normalized to the levels of glyceraldehyde-3-
phosphate-dehydrogenase (G3PDH) as constitutively expressed "house­
keeping" genes. Data represent mean values ± SD; n = 12. 
higher kinase activity. Elevated cdc protein most probably leads to 
hyperphosphorylation and inactivation of pRB. The underphos­
phorylated (i.e., active) pRB has strong transcriptional regnlatory 
functions and can up-regnlate TGFs and other growth control 
factors [34]. With reduced active pRB, the TGF-f31 levels would 
drop, leading to lack of growth regulation and eventual lesional 
growth. 
The above data demonstrate an up-regulation of proliferation but 
a down-regulation of differentiation and growth-suppressive signals 
in the presence of low-risk types of HPVs (Table I). Because 
experimental data suggest a negative effect of HPV s on cytokinel 
lymphokine secretion in vitro, we can assume that these changes are 
due to expression of viral genes [35]. The down-regnlation of 
TGF-�, TNF-a, and IFN-f3 is particularly interesting, as these 
�okin�s and others (such as granulocyte macrophage-colony­
stImulating factor, IL-ls, etc.) have the capacity to influence MHC 
class I and class II expression, and maybe antigen presentation [36]. 
. 
Ce�-mediated immunity is required to induce regression of 
VIrUs-infected cells. Gene products encoded by DNA viruses can 
alter .�HC expre�sion and perturb antigen recognition, potentially 
proVIding a selective advantage to the virus. In a primary immune 
response, the cellular immune system becomes sensitized to a virus 
infection only after viral proteins are degraded to short peptides and 
presented to � cells in the context ofMHC. In a memory response, 
a broader vanety of cells can present viral antigens to cytotoxic T 
cells, which lead to the lysis and clearance of the infected cell. In 
e�ther ev�nt, t�e ability to discriminate self molecules from foreign 
VIral anogens IS dependent on the presentation of the non-self 
peptides to T cells in the context of MHC [37]. 
MHC class I antigens are expressed on virtually all nucleated 
Table I. Early Cbanges in a "Low-Risk" HPV Infection 
Immune modula­
tory factors 
Increase 
Growth stimulatory pRB, cdc2 kinase, c-myc 
factors 
Decrease 
HLA-DR, HLA-B7, 
COta, CD4, CD8, 
IL-la, IL-l/3, 11-2, 
TGF-/3l, IFN-/3 
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Figure 2. mRNA levels of various genes of antigen presentation in 
condylomas. mRNA levels were determined by reverse transcriptase­
polymerase chain reaction using RNAs isolated from different condyloma 
specimens. The mRNA levels of those genes were normalized to the levels 
of glyceraldehyde-3-phosphate-dehydrogenase and are given as the per­
centage of normal. uninfected skin obtained from independent biopsy 
specimens. Data represent mean values ± SD; n = 12. 
cells. albeit at di1ferent levels. including keratinocytes of the 
squamous epithelium and epidermal dendritic cells. MHC class I 
molecules (e.g .• HLA-B7) present endogenous antigens to CDS+ 
cytotoxic T cells. MHC class II molecules (e.g .• HLA-DR) are 
present on professional antigen-presenting cells and can be induced 
on ectopic sites. e.g .• keratinocytes [38]. 
As shown in Fig Z. condylomas have very low levels of MHC 
class I and II mRNAs compared with uninfected skin. The signif­
icant decrease of CD1a mRNA (a marker for Langerhans cells) 
suggests a decline of Langer hans cells. in agreement with data in the 
literature [39]. Quantitative and morphologic changes of cutaneous 
Langerhans cells have been observed in condylomas. Because 
HLA-DR is mostly expressed by Langerhans cells and keratinocytes 
of condylomas. the net reduction is likely due to reduced numbers 
of Langer hans cells. Diminished levels ofIL-1a and 1L-1{3 further 
affect the ability of epidermal cells to present antigens . influencing 
dendritic Langerhans cells [35]. This lack of Langerhans cells 
probably hampers keratinocyte presentation of antigen, leading to a 
decrease in immunologic surveillance. 
The very low levels of IL-2 mRNAs in condylomas (Fig Z) 
further suggest a significant decrease in the numbers of lympho­
cytes, as 1L-2 expression is mainly due to their presence [40]. 
Indeed, CD4 and CDS mRNA levels are significantly lower in 
infected skin than in uninfected skin. Both CD4 + and CD8 + T 
cells have been observed to infiltrate HPV tumors, with a signifi­
cantly higher percentage ofCDS+ than ofCD4+ T cells. Tay et al 
[41] detected a lower helper/suppressor T-cell ratio in condyloma 
acuminata than in normal tissue. Our data showing that CD8 
mRNA exceeds CD4 mRNA levels in infected skin are in agree­
ment with these findings. This depletion of intraepithelial lympho­
cytes together with depletion of Langerhans cells. the selective 
depletion of CD4+ cells, and the resulting change in the ratio of 
CD4+ and CD8+ subsets , all support the suggestion that there is 
a local intraepithelial immune deficiency associated with HPV 
infection, which might facilitate a prolonged HPV infection and 
exert other long-term effects, such as malignancy. 
Suppression of class I MHC expression (e.g., HLA-B7) in 
HPV-infected cells may be virally mediated [42]. Given the extent 
to which MHC class I levels can be affected by indirect means, such 
as availability of stimulatory or inhibitory cytokines, care must be 
taken in assigning modulations of surface class I levels to direct 
"irus intervention. On the other hand, in vitro experiments have 
clearly demonstrated that the presence of HPV may contribute to 
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Figure 3. The presumed cutaneous immune response to a "low­
risk" HPV infection. TCR. T-cell receptor; LFA-l. lymphocyte func­
tion-associated antigen-1 . 
the loss of responsiveness of infected cells to potent MHC-inducing 
cytokines [35]. Therefore, the presence of HPV directly or indi­
rectly can influence MHC gene expression. A direct influence 
might be elicited through the expression of E7 or E5 early genes, 
which in vitro seem to interact with the antigen-processing system 
[37]. Another direct effect ofHPV gene products on MHC levels 
and antigen presentation might relate to a high abundance of early 
viral genes (especially E7). This differential expression can have 
multiple effects, leading to immunologic hyporesponsiveness. First, 
in vitro experiments have demonstrated that the HPV E7 proteins 
are masked in the infected cell nuclei, most probably because of 
complex formation with cellular proteins . The consequence of this 
masking might be inappropriate immune recognition, which might 
be the case in nonresponder tumors [43]. Second, the presentation 
ofE7 by keratinocytes, which lack co stimulatory molecules, might 
render E7-specific T cells anergic through peripheral tolerance 
[44).  Indirect effects ofE7 or other HPV early gene products might 
be exerted through affecting different cytokines (TGF-{3, TNF-a, 
IL-1, etc.) or oncogenes (c-myc), which then can influence MHC 
class I or II synthesis [45]. 
Upon an active immune response, HPV-infected keratinocytes 
release TNF-a, which is toxic to HPV replication and up-regulates 
expression of ICAM-1 on keratinocytes, attracting T cells. T-cell 
IFN-'Y up-regulates MHC, facilitating antigen presentation (Fig 3). 
We have also observed elevations ofTGF-{31, IFN-{3. and under­
phosphorylated (active) pRB, and reduced levels of cdc-2 kinase 
and c-myc after intralesional IFN treatment of HPV -infected sites 
[46], indicating a more complicated role ofIFN action. Of course, 
the effect of IFN might have been an initial immune modulatory 
effect, allowing the immune system to overtake the infection, 
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whereas the cytokine and anti-oncogene response is simply a 
reversal to nonnal status. 
HERPES SIMPLEX VIRUS (HSV) 
HSV 1 and 2 are DNA viruses with extensive cutaneous manifes­
tations, including interactions with SALT, leading to modulation of 
immunocyte subsets and the epidennal up-regulation of IL-l�, 
TNF-a, and lL-6 [47]. HSV types 1 and 2 cause a primary infection 
and then retire to respective neuronal ganglia and asymptomatically 
shed viral particles. In immunocompetent individuals, HSV remains 
in a latent phase, with only mild or subclinical reactivations. In 
immunocompromised patients, reactivation is more common and 
severe� One important question here is the role of SALT in 
preventing reactivation. 
Overcoming a cutaneous HSV infection requires intact antigen 
presentation and both CD4+ and CD8+ T cells [48]. One report 
has even isolated a CD4- CD8- y6 cytotoxic T-cell clone specific 
for HSV glycoprotein I [49] . In most viral infections, including 
HSV, CD8+ cytotoxic lymphocytes are major effector cells , but in 
asv, CD4+ cells are involved in both immune modulation and 
direct cell killing. Jennings et al [50] reported the requirement of 
CD4+ T cells in mounting a primary cytotoxic lymphocyte 
response to HSV infection and a similar requirement for the 
presence of CD4+ cells in a secondary cytotoxic lymphocyte 
response. 
CD4+ cells require antigen presentation in the context of MHC 
class n. Langerhans cells, keratinocytes, and infiltrating monocyte/ 
macrophage lineage cells are the predominant antigen-presenting 
cells of the epidermis . Williams et al [51] showed that although the 
epidermis is the primary site of HSV infection and serves as the 
predominant inoculation site, Langerhans cells failed to invoke 
HSV-specific proliferation ofT cells from naive animals, whereas 
splenic antigen-presenting cells could invoke a strong primary 
T-cell response. This suggests that epidennal Langerhans cells 
probably do not invoke the primary T-cell response against HSV, 
but acquire the ability only after maturation in an extraepidennal 
site. This time lag might allow the HSV infection to reach nerve 
endings, where the virus can enter the protective dorsal ganglia. 
Williams et al [51] showed a strong ability of Langerhans cells to 
invoke a secondary T-cell proliferative response to HSV, which 
was abrogated by anti-MHC class n antibodies and complement. 
Therefore, both the primary and secondary (i.e., memory) T-cell 
responses to HSV require HSV presentation in the context ofMHC 
class n. Langerhans cells can invoke a memory T-cell response to 
HSV comparable to that of splenic antigen-presenting cells, indi­
cating that Langerhans cells might be responsible for suppression of 
HSV reactivation. 
Cunningham and Noble [52] reported the ability ofHLA-DR+ 
keratinocytes to invoke a secondary T-cell response, made up of 
CD4+ and CD8+ cytotoxic cells. Most probably, keratinocytes , 
infiltrating monocyte/macrophages, and dendritic cells only aug­
ment the immune response; Langerhans cells are the main scaven­
ger cells of the epidermis. Only after cytokine release of immuno­
cytes do keratinocytes express HLA-DR and monocyte/ 
macrophages infiltrate. Furthennore, that CD4+ T cells have such 
a pivotal role in both cytokine-mediated immune modulation 
"help" and direct and indirect cytotoxicity supports the report by 
Heng et al [6] indicating a more extensive HIV-l infection in the 
presence of HSV-1. HSV-l infection activates CD4+ cells, ren­
dering them susceptible to HIV infection, which leads to an 
ultimate reduction in CD4+ counts, possibly reflected in the more 
aggressive HSV infections in HlV -infected patients. 
A further layer of complexity has been found recently involving 
CD4+ T helper (Th) subsets in HSV infection . CD4+ Th cells 
have been categorized into two major subsets, Thl and Th2 [53]. 
The Thl cells secrete mainly IL-2, IFN-y, and TNF, whereas Th2 
cells secrete mainly IL-4, IL-5, and lL-l0. Thl cells are generally 
efficient in controlling viral and intracellular pathogens, whereas 
Th2 cells, by augmenting humoral immunity, better control bac­
terial and parasitic infections. The differences between Thl and 
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Th2 in skin, and their involvement in cutaneous disease, have been 
demonstrated [54]. Jayaraman et al [55] recently reported the 
involvement of Th2 cells in HSV -induced human stromal keratitis 
(HSK). 
HSK is due to an inflanunatory response to HSV-l infection of 
the cornea, leading to scarring and blindness. Not only are CD4+ 
cells involved in the lesions, but, using the mouse model for HSK, 
Jayaraman et al [55] raised an HSV g-D-specific T-cell clone that 
increased both the onset and severity ofHSK. The CD4+ T-cell 
clone was MHC class II-restricted and produced lL-4; i.e., it 
belonged to the Th2 subtype. Although Th subtypes have not been 
studied in cutaneous HSV infections, the above report is sufficient 
reason to warrant an investigation of the role of Th subtypes in 
HSV infections. In a recently published and controversial article, 
Maggi et til [56] reported that HIV preferentially replicates in Th2 
cells. Therefore, the role of cutaneous Th2 in HSV might explain 
the increased incidence of HSV in HIV coinfections, highlighting 
the importance of CD4+ T cells in both viral infections. 
CONCLUSION 
The immune system resident in the epidermis is significantly 
affected by infections with HIV, HPV, and HSV. SALT is able to 
eradicate a cutaneous viral infection and retain memory of the 
infection to ward off future infections, but in certain instances, 
SALT does the opposite and enhances the pathology of a cutaneous 
viral infection. One common feature in HIV, HPV, and HSV 
infections is reduction in epidennal Langerhans cell counts, but this 
does not indicate a common mechanism. For example, HlV is 
known to infect Langerhans cells and have cytopathic effects, but 
this has not been shown for HPV or HSV. Possibly, viral infections 
of the epidennis require the presence of Langerhans cells only in 
extraepidennal sites (e.g., lymph nodes), where antigen processing 
takes place . The three viruses affect epidennal T-cell counts and 
subset proportions differently, which may indicate differential cy­
tokine levels or patterns of expression in different viral infections. 
Although much has been leamed about cutaneous viral immunol­
ogy during the past few years, further studies are needed to enhance 
our understanding of SALT in viral infections. 
This work was supported by the James W. McLaughlin Fellows/tip Fund (OMM) 
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